title: Monoolein and chitosan gels as potential carriers of the rhBMP-2, using decortication surgical technique in Wistar rats as experimental model.
abstract: The purpose of this work was to evaluate the new bone tissue, comparing two different carriers for rhBMP-2, monoolein and chitosan gels, using the decortication and nondecorticatication surgical technique in rat mandibles, evaluated by histomorphometrical method. It was used 56 male Wistar rats (300 g), divided into 8 groups according to the rhBMP-2 carrier used, monoolein or chitosan gels; surgical technique, bone decortication or nondecortication; and period of time, 3 or 6 weeks until the sacrifice by perfusion. Results obtained in this study showed that the rhBMP-2/monoolein and rhBMP-2/chitosan used in this experimental model was able to induce osteogenesis, contributing to the bone healing process. The bone repair process was time dependent, so that at 6 weeks there was an improved amount of new bone in relation to 3 weeks, considered each analyzed group, and the decortication was able to expose the bone marrow and speed up the bone healing process, which was showed by histomorphometrical methods. Both of carriers were capable to adapt to the bone surgical area, according to the clinical observations, and had favorable properties in relation to protein releasing, revealed by the amount of new bone tissue found in the histological analysis.
authors: Faculdade de Odontologia de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil. jpmissa@forp.usp.br
authors: João Paulo Mardegan
authors: JP
authors: Issa
authors: Augusto César Cropanese
authors: AC
authors: Spadaro
authors: Maria Vitória L B
authors: MV
authors: Bentley
authors: Mamie Mizusaki
authors: MM
authors: Iyomasa
authors: Selma
authors: S
authors: Siéssere
authors: Simone Cecílio Hallak
authors: SC
authors: Regalo
authors: Helton Luiz Aparecido
authors: HL
authors: Defino
mesh_terms: D000818:Animals; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D048271:Chitosan / Q000378:metabolism* / Q000494:pharmacology; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000378:metabolism* / Q000494:pharmacology; D005782:Gels / Q000737:chemistry*; D005989:Glycerides / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D008297:Male; D008334:Mandible / Q000166:cytology / Q000601:surgery; D010012:Osteogenesis / Q000187:drug effects*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000494:pharmacology*; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
chemical_list: D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D004337:Drug Carriers; D005782:Gels; D005989:Glycerides; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D048271:Chitosan; C005953:monoolein